Greenberg Traurig is a proud diamond sponsor of the Israel Innovation Conference. This event will be the first in the world where Biomed and Hi-tech will join hands in a unique and exciting new international conference format.
Organized by Israel Ministry of Industry Trade and Labor to the U.S., Greenberg Traurig will be hosting an Israeli Medical Device and Bio-Pharma delegation on Tuesday, December 10th from 8-10 a.m. in the Greenberg Traurig Garden Room, One International Place, 20th floor, Boston, MA.
Welcome to the second issue of the Greenberg Traurig Life Sciences & Medical Technology Newsletter, a quarterly collection of articles and Alerts written by GT attorneys and focused on significant life sciences, medical technology and healthcare industry developments.
Welcome to the first issue of the Greenberg Traurig Life Sciences & Medical Technology Newsletter, a quarterly collection of articles and Alerts written by GT attorneys and focused on significant life sciences, medical technology and healthcare industry developments.
We are pleased to share with our readers the GT Alert – — Private Placement of Alternative Investment Funds in the EU: Changing Regulatory Landscape, that details the guidelines of the European Union’s Alternative Investment Fund Managers Directive (AIFMD) and their effect on the regulatory landscape in each EU jurisdiction.
This Alert was prepared by Wietse de Jong and Ilana Haramati, with the assistance of GT offices in London and Warsaw, its highly applicable to investors who are seeking to establish investments funds in each EU jurisdiction in the future.
GT Israel is pleased to announce that David Schulman, a shareholder in our Atlanta office and an active member of our Israel Practice Group, has been appointed to the Executive Committee of the American-Israel Chamber of Commerce (AICC), Southeast Region. David, a native Hebrew speaker, practices in the firm’s Corporate & Securities Department and provides a variety of commercial and technology-related legal advice and support to companies in Israel and abroad. The AICC, Southeast Region was established in 1992 as a private, not-for-profit organization with the goal of helping companies in Israel and the American Southeast (Georgia, Alabama, North Carolina, South Carolina, Tennessee, and Mississippi) to develop stronger business relationships and explore new market opportunities. Today, with over 500 members, the AICC, Southeast Region is regarded as one of the most successful bi-national business organizations in the U.S. and has helped facilitate over $1 billion in transactions between Israeli and American companies.
Rule 13q-1 under the Securities Exchange Act of 1934, adopted by the SEC in August 2012 as part of the Dodd‐Frank mandate, was vacated by the U.S. District Court for the District of Columbia on July 2nd, 2013. The rule, which imposed annual reporting requirements on “resource extraction issuers” relating to payments made to a foreign government or to the U.S. federal government in connection with the commercial development of oil, natural gas or minerals, is now void and the SEC must either propose a new rule or appeal the decision. A court decision on the conflict minerals rule is expected shortly.
We invite our readers to read the GT Alert — U.S. District Court Vacates SEC Rule on Extractive Industries Disclosure Requirements; Issuers Await Decision on Conflict Minerals Rule prepconflict mineralsared by Barbara A. Jones.
On July 10, 2013, the Securities and Exchange Commission (SEC) adopted rule amendments that eliminate the 80-year old prohibition on general solicitation and general advertising in Rule 506 and Rule 144A transactions under the Securities Act of 1933, as amended (Securities Act), and prohibit issuers from reliance on Rule 506 for any offering in which certain felons and other bad actors are involved. In related action, the SEC released proposed rules that would, among other things, require issuers to provide additional information in connection with the use of general solicitation in Rule 506 offerings.
These amendments will likely have major effects on how private placements are conducted and should facilitate much broader access to the capital markets for a wide variety of issuers, both public and private. As a result, it is extremely applicable to both public and private Israeli companies seeking to gain access to U.S. capital markets.
We invite our readers to read the GT Alert — SEC Lifts Ban on General Solicitation in Certain Private Securities Transactions; Disqualifies ‘Bad Actors’ from Rule 506 Offerings prepared by Barbara A. Jones, Spencer G. Feldman, Ira N. Rosner, Steven Felsenstein and Jean E. Harris.
On Monday, June 10, GT Israel was pleased to host Robert Josefsberg, past-President and current member of the International Academy of Trial Lawyers (IATL). The IATL is composed of elite trial lawyers (including both plaintiffs’ and defense counsel) from the United States and 30 other countries. The IATL serves to promote the rule of law internationally and support legal reform where needed. Fellowship in the IATL is by invitation only and is limited to 500 active trial lawyers. As part of its global mission, the IATL is hoping to expand its membership in Israel and encourage the cross-border participation and involvement of leading Israeli trial counsel.
This Wednesday, April 24, the New England Israel Business Council (NEIBC) is presenting “Trends & Challenges in the Israeli Med-Tech Arena” breakfast seminar on this Wednesday, April 24 from 8:30 – 10:00 am at Greenberg Traurig, One International Place in Boston. The featured speaker is Elka Nir, Managing Director, Life Sciences at Giza Venture Capital. Greenberg Traurig is sponsoring the event which is free to attend. GT Patent Attorneys David Dykeman and Roman Fayerberg will be speaking on Med-Tech industry trends in IP, Regulatory, and M&A. See details of the invitation here.